Cost of tumor necrosis factor blockers per patient with rheumatoid arthritis in a multistate Medicaid population

por Bonafede, Machaon, Joseph, George J, Shah, Neel, Princic, Nicole, Harrison, David J
Publicado 2014

Costs of Tumor Necrosis Factor Blockers Per Treated Patient Using Real-World Drug Data in a Managed Care Population

por Schabert, Vernon F., Watson, Crystal, Joseph, George J., Iversen, Paige, Burudpakdee, Chakkarin, Harrison, David J.
Publicado 2013

Further evaluation of a claims-based algorithm to determine the effectiveness of biologics for rheumatoid arthritis using commercial claims data

por Curtis, Jeffrey R, Chastek, Benjamin, Becker, Laura, Harrison, David J, Collier, David, Yun, Huifeng, Joseph, George J
Publicado 2013

Assessing utility values for treatment-related health states of acute myeloid leukemia in the United States

por Stein, Eytan M., Yang, Min, Guerin, Annie, Gao, Wei, Galebach, Philip, Xiang, Cheryl Q., Bhattacharyya, Subrata, Bonifacio, Gaetano, Joseph, George J.
Publicado 2018

Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis

por Cannon, Grant W., DuVall, Scott L., Haroldsen, Candace L., Caplan, Liron, Curtis, Jeffrey R., Michaud, Kaleb, Mikuls, Ted R., Reimold, Andreas, Collier, David H., Joseph, George J., Harrison, David J., Sauer, Brian C.
Publicado 2016